Pricing Log in Create free account
Friday 6 November 2026 Export VCYT’s income statement to Excel — free account

Veracyte, Inc.

VCYT Healthcare Diagnostics & Research

Veracyte, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $517.1 million, up 16.0% from fiscal 2024.

Revenue
+15.1%
EPS
+62.5%
Free cash flow
−9.63%

Quarter to September 2026, against a year earlier

24.04 0.04 +0.17%
Market cap
$1.9B
P/E
15.2×
Fwd P/E
45.2×
Dividend yield
—
F-score
8/9
Altman Z
21.08
Beneish M
−2.66
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Sold, $m 18.63
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell 6 — — 5 — 3 5 — — 7 2 —
Insider Ownership 1.96%

Capital & Financial Ratios $m

Size
Market Cap 1,930.00
Revenue ttm 581.78
Net income ttm 126.85
Free cash flow ttm 161.95
Net debt Q (485.23)
Valuation
P/E 15.16
Forward P/E 45.20 (above 35: high)
Price / sales 3.34
Forward P/S Powerpack
Price / FCF 11.98
Price / book 1.35
Financial health
Current ratio Q 5.56 (at or above 1.5: strong)
Debt / equity Q 0.00 (at or below 0.5: strong)
Interest coverage Q (15.33)
Growth
Revenue growth Q +15.08% (above 0%: growing)
Operating income growth Q −27.79% (below 0%: shrinking)
EPS, this year +7.99%
EPS, next year A −8.03% (below 0%: weak)
Revenue, next year A +14.82% (at or above 10%: strong)
EPS, past 5 yrs —
EPS, next 5 yrs A +3.06%

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 2.5×, against a ten-year median of 5.2×; over the ten years it ranged from 2.3× in 2016 to 25.1× in 2021.
P/S against its own 10 years 11.66%
10-year low 10-year high
P/B against its own 10 years 3.52%
10-year low 10-year high
EV/Sales against its own 10 years 4.36%
10-year low 10-year high
EV/FCF against its own 10 years 0.11%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 216 289 413 —
Receivables 40 47 45 57
Inventory 16 22 21 —
Other — — — —
286 372 488 468
2023 2024 2025 Q'26
Payables 13 9 5 10
ST’ Debt — — — —
Other 3 17 1 —
61 79 60 84

Compound Annual Growth %

10y 5y 3y
Sales 26.44% 34.50% 20.37%
Cash Flow 0.00% 0.00% 162.51%
Earnings 0.00% 0.00% 0.00%
Book Value 38.27% 25.46% 6.79%

Earnings Trends EPS, adjusted, against the consensus

Q3 FY26 Estimate 0.44 Actual 0.51

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q4 FY25 0.41 0.53 Beat by 0.12
Q1 FY26 0.34 0.52 Beat by 0.18
Q2 FY26 0.43 0.54 Beat by 0.11
Q3 FY26 0.44 0.51 Beat by 0.07
Q4 FY26 0.47 — Reports 24 February 2027

EPS $

Mar Jun Sep Dec Year
’26 0.35 0.31 0.38 — —
’25 0.09 (0.01) 0.24 0.51 0.82
’24 (0.02) 0.07 0.19 0.06 0.31
’23 (0.11) (0.12) (0.41) (0.39) (1.02)
’22 (0.20) (0.13) (0.12) (0.05) (0.51)
’21 (0.66) (0.13) (0.20) (0.15) (1.11)
’20 (0.24) (0.22) (0.08) (0.14) (0.66)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 139 150 152 — —
’25 114 130 132 141 517
’24 97 114 116 119 446
’23 82 90 90 98 361
’22 68 73 76 80 297
’21 37 55 60 67 220
’20 31 21 31 35 117
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 35 46 40 — —
’25 5 34 45 53 136
’24 (9) 30 30 25 75
’23 (2) 17 14 16 44
’22 (9) 0 7 10 8
’21 (41) 2 (1) 8 (32)
’20 (5) (8) 2 2 (10)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 32 43 38 — —
’25 4 32 42 49 127
’24 (11) 27 28 20 64
’23 (3) 13 11 13 34
’22 (11) (3) 5 8 (1)
’21 (42) 0 (3) 8 (37)
’20 (6) (9) 1 1 (13)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1.3
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Sep ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 65 72 92 120 117 220 297 361 446 517 582 +25.9% 594 660 730 +12.2%
Gross margin, % 60.88 60.81 64.05 69.66 64.71 66.11 59.24 63.62 66.88 70.10 71.98 +9.2 pt
EBT (31) (31) (23) (13) (35) (82) (36) (77) 26 68 118 n/m
EBT margin, % (48.18) (43.09) (25.00) (10.47) (29.71) (37.20) (12.28) (21.22) 5.78 13.19 20.33 +61.4 pt
Net income (31) (31) (23) (13) (35) (76) (37) (74) 24 66 127 n/m
Per share, $
Per share, $ Revenue 2.26 2.12 2.49 2.61 2.21 3.23 4.14 4.97 5.83 6.58 7.23 +12.6%
Earnings (1.09) (0.91) (0.62) (0.27) (0.66) (1.11) (0.51) (1.02) 0.32 0.84 1.59 n/m
Cash flow (0.97) (0.70) (0.37) (0.07) (0.18) (0.47) 0.11 0.61 0.98 1.73 2.16 n/m
Capex (0.15) (0.04) (0.05) (0.06) (0.05) (0.08) (0.12) (0.14) (0.15) (0.12) (0.15) (1.9%)
Free cash flow (1.12) (0.74) (0.42) (0.13) (0.24) (0.54) (0.01) 0.47 0.83 1.61 2.01 n/m
Book value 2.07 1.10 2.15 5.19 7.91 16.15 15.03 14.37 15.38 16.66 17.80 +26.1%
Shares, m 29 34 37 46 53 68 72 73 76 79 80 +11.8%
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 123.75 50.12 15.16 17.4
P/S 3.48 3.17 5.06 10.70 22.18 12.74 5.47 5.51 6.79 6.40 3.34 8.1
P/B 3.80 6.12 5.84 5.38 6.19 2.55 1.51 1.91 2.58 2.53 1.35 3.8
EV/Sales 2.98 3.07 4.49 9.40 19.23 11.95 4.87 4.92 6.15 5.60 2.51 7.3
EV/FCF (6.02) (8.75) (26.83) (189.60) (180.03) (70.87) (1,424.06) 51.84 42.97 22.88 9.00 (178.8)
Cash, $m
Cash, $m Operating cash flow (28) (24) (14) (3) (10) (32) 8 44 75 136 174 n/m
Capex (4) (1) (2) (3) (3) (5) (9) (10) (11) (10) (12) +9.7%
Free cash flow (32) (25) (15) (6) (13) (37) (1) 34 64 127 162 n/m
Balance, $m
Balance, $m Working capital 62 42 84 170 359 179 186 224 294 428 384 +23.9%
Net debt (34) (9) (53) (158) (347) (176) (179) (216) (289) (413) (485) +32.0%
Shareholders’ equity 60 37 80 239 421 1,097 1,075 1,044 1,176 1,310 1,433 +41.0%
Returns, %
Returns, % ROA (35.58) (34.50) (23.08) (6.37) (9.53) (9.19) (3.12) (6.55) 2.00 4.90 8.63 +40.5 pt
ROIC (69.89) (58.03) (51.39) (11.55) (29.62) (5.56) (2.86) (6.48) 1.14 4.03 4.33 +73.9 pt
ROE (56.59) (64.05) (39.32) (7.89) (10.57) (9.96) (3.37) (7.02) 2.17 5.34 9.43 +61.9 pt
People
People Employees 216 246 270 354 320 761 787 815 824 755 — +14.9%
Revenue/emp, $m 0.30 0.29 0.34 0.34 0.37 0.29 0.38 0.44 0.54 0.68 — +9.6%
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 5 Nov 2026

Veracyte, Inc. vs peers in Diagnostics & Research (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
RDNT RadNet, Inc. $6.1B — (loss-making) 1,050× +24.99% (above 0%: growing) −47.37% (below 0%: shrinking) −43.22% (below 0%: shrinking) 14.14% 6.34% Compare
GRAL GRAIL, Inc. $5.3B — (loss-making) — (loss-making) +3.71% (above 0%: growing) n/m −24.90% (below 0%: shrinking) 0.00% (385.29%) Compare
BLLN BillionToOne, Inc. $5.3B 88.7× 146× +47.24% (above 0%: growing) +164.29% (above 0%: growing) +9.25% (above 0%: growing) 70.86% 8.96% Compare
SHC Sotera Health Company $4.5B 26.3× 26.4× +4.36% (above 0%: growing) +20.12% (above 0%: growing) +64.98% (above 0%: growing) 55.65% 34.98% Compare
ADPT Adaptive Biotechnologies Corporation $4.3B — (loss-making) — (loss-making) −10.72% (below 0%: shrinking) −66.67% (below 0%: shrinking) +201.86% (above 0%: growing) 76.24% (0.54%) Compare
CDNA CareDx, Inc. $4.0B 30.9× 36.2× +39.29% (above 0%: growing) +1,133.33% (above 0%: growing) −68.62% (below 0%: shrinking) 71.09% 5.82% Compare
NEO NeoGenomics, Inc. $2.1B — (loss-making) — (loss-making) +11.43% (above 0%: growing) n/m −3,724.21% (below 0%: shrinking) 46.16% (3.79%) Compare
VCYT Veracyte, Inc. $1.9B 15.2× 45.2× +15.08% (above 0%: growing) +62.50% (above 0%: growing) −9.63% (below 0%: shrinking) 70.58% 10.92%
WGS GeneDx Holdings Corp. $1.9B — (loss-making) — (loss-making) +11.44% (above 0%: growing) n/m −585.59% (below 0%: shrinking) 68.37% (15.25%) Compare
Median of peers $4.4B 30.9× 91.1× +11.44% +20.12% −34.06% 62.01% 2.64%

All 49 Diagnostics & Research stocks →

Pay and ownership Proxy statement filed 22 April 2026

Chief executive’s pay

Year Total pay Actually paid $100 invested
2025 7.42m 9.61m 86.02

Ownership

Directors and executive officers, together 1.60%
BlackRock, Inc. 15.00%
Artisan Partners Limited Partnership 7.80%
FMR LLC 7.10%
State Street Corporation 5.30%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Veracyte, Inc. (VCYT) Latest News

6 Nov

Impact 3 · · Zacks

5 Nov

Impact 3 · · The Motley Fool transcript
Impact 3 · · GuruFocus.com
Impact 3 · · MarketBeat transcript

4 Nov

Impact 3 · · Associated Press
Impact 3 · · GlobeNewswire

29 Oct

Impact 3 · · GlobeNewswire
Impact 3 · · Zacks

28 Oct

Impact 4 · · Zacks
Impact 4 · · Simply Wall St.

23 Oct

Impact 4 · · GlobeNewswire

21 Oct

Impact 3 · · Zacks

19 Oct

Impact 4 · · GlobeNewswire

16 Oct

Impact 4 · · GlobeNewswire

9 Oct

Impact 4 · · Simply Wall St.

2 Oct

Impact 4 · · Simply Wall St.
Impact 3 ·

1 Oct

Impact 4 · · Simply Wall St.

29 Sep

Impact 4 · · GlobeNewswire

25 Sep

Impact 4 · · GlobeNewswire
Impact 4 · · Zacks

14 Sep

Impact 4 ·

26 Aug

Impact 3 ·

31 Jul

Impact 4 · · MarketBeat
Impact 4 · transcript
Impact 3 ·

30 Jul

Impact 4 ·
Impact 3 ·
Impact 3 ·

23 Jul

Impact 3 ·

VCYT metrics, ten years each

stockrow.com/VCYT · Data as of Nov 5, 2026 · For information only; not investment advice. · © 2026 stockrow.com